BioMaxima S.A. (WSE:BMX)

Market Cap	59.96M
Revenue (ttm)	56.60M
Net Income (ttm)	874.00K
Shares Out	4.19M
EPS (ttm)	0.21
PE Ratio	68.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,035
Average Volume	11,261
Open	13.40
Previous Close	13.40
Day's Range	13.25 - 14.35
52-Week Range	10.55 - 20.50
Beta	0.46
RSI	54.48
Earnings Date	Jun 3, 2025

About BioMaxima

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and r...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 126
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2024, BioMaxima's revenue was 52.85 million, an increase of 12.96% compared to the previous year's 46.79 million. Earnings were 535,000, a decrease of -8.70%.